Amendment to European Addendum to the Clinical Trial Agreement Between Medtronic and ARCA dated July 10, 2017
[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended
Exhibit 10.1
User SAP Number:
Region:
AMENDMENT TO
EUROPEAN ADDENDUM
TO THE CLINICAL TRIAL COLLABORATION AGREEMENT
BETWEEN MEDTRONIC AND ARCA
This Amendment, effective July 10, 2017, amends the European Addendum to the Clinical Trial Collaboration Agreement between Medtronic, Inc. (“Medtronic”) and ARCA biopharma, Inc. (“ARCA“), which became effective September 14, 2016 (“Agreement”).
| 1. | Exhibit A to the Agreement is deleted and replaced with the attached Exhibit A-1. |
Except to the extent provided above, the remaining terms and conditions of the Agreement shall remain in full force and effect.
| MEDTRONIC, INC. 8200 Coral Sea St NE(MVS23) Mounds View, MN 55112 United States Attn: Email: Fax: | ARCA biopharma, Inc. 11080 CirclePoint Rd, Suite 140 Westminster, Colorado 80020 United States Attn: Email: Fax: |
| By/s/ Chris Landon
Print Name Chris Landon
Print TitleVP & GM, Diagnostics, Medtronic
DateApril 30, 2017
| By/s/ Chris Ozeroff
Print Name Chris Ozeroff
Print TitleSVP
DateApril 24, 2017
|
EUROPEAN ADDENDUM EXHIBIT A-1
Exhibit A to Clinical Trial Collaboration Agreement
Version: 5 July 2017
| Agreed (signature/date): | /s/ Melody LaBeau 10 July, 2017 |
|
|
| /s/ Christopher Dufton | |
|
| Medtronic | Melody LaBeau |
|
| ARCA | Christopher Dufton, PhD |
[*]
[*] = Certain confidential information contained in this document, marked by brackets is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended
Page 2 of 2
